Research Updates

Researchers now view glaucoma as a disease of the brain — a neurodegenerative disease — rather than simply an eye disease.

A study published by Andrew D. Huberman, PhD and Rana N. El-Danaf, PhD points to the specific structural features and cell types in the retina that may act as key factors in glaucoma progression.

We hope to one day restore vision lost from glaucoma, but that can’t presently be done.

Derek Welsbie, MD, PhD was awarded the 2014 Shaffer Prize for Innovative Glaucoma Research for his study “Evaluating the Role of the c-Jun N-terminal Kinase Cascade in Retinal Ganglion Cell Death.”

“We believe this is an important step toward a new and powerful treatment option for glaucoma patients who are going blind despite efforts to lower or manage their eye pressure.” — David Calkins, PhD

What can we do when patients have lost functional vision in glaucoma?

Catalyst for a Cure is a unique approach to research developed by Glaucoma Research Foundation to accelerate the pace of discovery toward a cure for glaucoma.

What is a biomarker? A biomarker is an indicator of a biological condition that, in some cases, can assist in the diagnosis and management of disease.